SHL Group is looking forward to exhibiting at the 2019 Pharmapack, Europe’s dedicated pharmaceutical packaging and drug delivery event from 6-7 February in Paris, France.

At the centre of this year’s exhibition is Molly 2.25, SHL’s high volume variation of its classic Molly auto injector, designed with a preconfigured technology to help pharmaceutical companies minimise initial equipment investments and speed up development timelines. Boasting an intuitive design that meets a variety of patient handling profiles, Molly 2.25 supports the trend for injection volumes in the 1-2.25mL range to meet the increasing need for the simple delivery of larger doses. SHL is also looking forward the market introduction of the first drug product based on the Molly 2.25 programme.

Another highlight at this year’s event is the range of auto injectors built with SHL’s Needle Isolation Technology (NIT). This proprietary technology allows cartridge-based injection devices to be built as easy-to-use auto injectors with permanently hidden needles. "The NIT is a true problem solver because cartridges not only open up a world of opportunities for pharma companies, it also offers patients a safe and intuitive experience without sacrificing usability," said Magnus Fastmarken, SHL’s global director of marketing.

This year, SHL is again pairing up with Innovation Zed to present InsulCheck at Pharmapack’s Innovation Gallery. This year’s display, InsulCheck Connect, is a smart pen injector add-on that displays the time elapsed since last injection. It can be connected to third party service applications to track insulin injection. InsulCheck Connect is compatible with a variety of existing insulin injection pens on the market and can be customised to support other pen injector projects.

Visitors are invited to explore SHL’s innovative injectable drug delivery solutions at Stand B44 at the Paris Expo Porte de Versailles.